What is Kilitch Drugs (India) Ltd (KILITCH) share price return in the past 10 years?

Kilitch Drugs (India) Ltd share price has appreciated 26.8% annually (CAGR) over the past ten years.

What is the share price of Kilitch Drugs (India) Ltd (KILITCH)?

Company share prices are keep on changing according to the market conditions. The current trading price of Kilitch Drugs (India) Ltd (KILITCH) on 04-Jun-2026 16:59:59 at 16:59 is 179.00.

What is the P/E ratio of Kilitch Drugs (India)?

The latest standalone P/E ratio of Kilitch Drugs (India) as of 04-Jun-2026 is 19.32.

What is the P/B ratio of Kilitch Drugs (India) Ltd (KILITCH)?

The latest standalone P/B ratio of Kilitch Drugs (India) Ltd (KILITCH) as of 04-Jun-2026 is 1.88.

What is the 52-week high and low of Kilitch Drugs (India) Ltd (KILITCH)?

The 52-week high of Kilitch Drugs (India) Ltd (KILITCH) is Rs. 245.00 and the 52-week low is Rs. 121.10.

Kilitch Drugs (India) Ltd (KILITCH) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Kilitch Drugs (India) Ltd (KILITCH)
Brand: Kilitch Drugs (India)

Kilitch Drugs (India) Ltd (KILITCH)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524500 NSE: KILITCH Pharmaceuticals & Drugs | Small Cap | Kilitch Drugs(India) Share Price

Kilitch Drugs (India) Ltd (KILITCH)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524500 NSE: KILITCH Pharmaceuticals & Drugs | Small Cap | Kilitch Drugs(India) Share Price

Key Metrics

Valuation Multiples

Market Cap

₹626 Cr.

Current Price

₹179

52-Week Low / High

₹121 / 245

TTM EPS

₹9.3

TTM Sales

₹189 Cr.

Book Value per Share

₹95.3

P/E Ratio

19.32

Lower than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

1.88

In line with its 5-year historical median

Price to Sales (P/S)

3.32

In line with its 5-year historical median

EV/EBITDA

15.21

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

13.11%

Outperforms industry median

Return on Capital Employed (ROCE)

15.49%

Outperforms industry median

Return on Assets (ROA)

9.73%

Operating Profit Margin

17.1%

Net Profit Margin

17.16%

Gross Profit Margin

23.4%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

37.99%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

52.4%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

77.35%

Asset Quality

Promoter Holding

63.77%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹298 Cr.

Equity

₹35 Cr.

Face Value

₹10

All Time Low / High

₹0.37 / 245.00

Kilitch Drugs (India) stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Kilitch Drugs (India) Ltd a good quality company?

Kilitch Drugs (India) Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Kilitch Drugs (India) Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Kilitch Drugs (India) Ltd vs industry peers?

Kilitch Drugs (India) Ltd revenue CAGR is 24.47%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Kilitch Drugs (India) Ltd?

Promoters hold 63.77% of the Kilitch Drugs (India) Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Kilitch Drugs (India) Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 25.6% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-2%	-0.3%	6%	13.8%	3.8%	4.9%	7.8%	9.9%	10.8%	15.5%	-
Value Creation Index ⓘ	-1.2	-1.0	-0.6	0.0	-0.7	-0.7	-0.4	-0.3	-0.2	0.1	-
Growth Parameters ⓘ
Sales ⓘ	21	28.1	50.5	96.4	60.8	70	105	118	132	182	189
Sales YoY Gr.	-	33.9%	79.3%	91.1%	-37%	15.2%	50.2%	12%	11.7%	38%	-
Adj EPS ⓘ	-0.8	0.1	1.8	4.1	0.7	1.5	2.9	4.4	4.6	7.5	9.3
YoY Gr.	-	NA	1358.3%	136.6%	-84.1%	121.2%	101.4%	49%	4.8%	63.2%	-
BVPS (₹) ⓘ	43.1	43.5	45.4	47.8	47.7	51.3	55	59.8	67.7	76.9	95.3
Adj Net Profit ⓘ	-2.3	0.3	4.9	13	2.1	4.6	9.4	13.9	15.1	24.6	32
Cash Flow from Ops. ⓘ	18	0.6	-1.3	7.4	7.3	6.1	5.2	6.1	-2.6	15.2	-
Debt/CF from Ops. ⓘ	0	1.1	-0.6	1.3	1.7	2.4	3.9	3.6	-12.1	3.2	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	27.1%	24.5%	20%	38%
Adj EPS ⓘ	NA	62.6%	36.6%	63.2%
BVPSⓘ	6.6%	10%	11.8%	13.5%
Share Price	26.8%	17.5%	20.8%	-16.5%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-1.9	0.3	3.9	9.2	1.4	3	5.5	7.5	7.2	10.4	10.8
Op. Profit Mgn % ⓘ	-15	0.5	11.1	17	1.9	7.6	11.3	14.7	15.5	17.1	17.2
Net Profit Mgn % ⓘ	-10.7	1.2	9.8	13.5	3.4	6.6	8.9	11.8	11.5	13.6	17.2
Debt to Equity ⓘ	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2
Working Cap Days ⓘ	536	280	193	173	373	364	299	314	319	285	180
Cash Conv. Cycle ⓘ	244	163	86	64	107	59	39	32	55	58	101

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	21	28	50	96	61	70	105	118	132	182
Operating Expenses ⓘ +	25	29	45	81	60	65	94	100	111	150
Manufacturing Costs	4	4	3	4	5	5	8	8	7	8
Material Costs	9	11	26	53	36	39	60	58	66	92
Employee Cost	3	3	4	5	6	5	6	7	8	10
Other Costs ⓘ	9	10	11	18	13	15	20	27	30	40
Operating Profit ⓘ	-4	-1	6	16	1	5	11	17	20	31
Operating Profit Margin (%)	-16.9%	-2.0%	11.1%	16.2%	1.9%	7.6%	10.6%	14.7%	15.5%	17.1%
Other Income ⓘ +	3	2	3	6	6	4	5	5	6	14
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0	1	1	1	1	1	2	2
Depreciation ⓘ	2	1	1	1	1	1	1	1	1	2
Profit Before Tax ⓘ	-2	-0	7	20	5	8	14	19	23	41
Tax ⓘ	-0	-0	1	5	1	1	3	4	6	10
Profit After Tax	-2	-0	6	15	4	6	11	16	18	31
PAT Margin (%)	-9.8%	-0.1%	12.3%	15.3%	7.3%	8.8%	10.0%	13.3%	13.4%	17.2%
Adjusted EPS (₹)	-0.8	-0.0	2.2	4.7	1.4	1.9	3.3	4.9	5.4	9.5
Dividend Payout Ratio (%)	0%	0%	11.10%	5.20%	0%	0%	0%	0%	0%	0%

Valuation of Kilitch Drugs(India) - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	117	118	127	150	150	163	175	191	223	253
Share Capital ⓘ	13	13	14	15	15	15	16	16	16	16
Reserves ⓘ	103	104	114	135	135	147	160	175	206	237
Debt +	0	1	1	9	13	15	20	22	31	49
Long Term Debt	0	0	0	0	0	0	0	0	0	28
Short Term Debt	0	1	1	9	13	15	20	22	31	21
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4	6	8	5	8	14	28	29	26	47
Others Liabilities ⓘ	4	4	8	6	2	4	8	9	5	6
Total Liabilities ⓘ	125	128	144	171	173	195	231	250	285	355
Fixed Assets
Net Fixed Assets ⓘ +	8	8	7	8	8	7	14	15	16	20
Gross Block	23	24	25	26	27	28	36	38	40	46
Accumulated Depreciation	15	16	17	18	20	21	22	23	24	26
CWIP ⓘ	0	0	0	0	0	0	0	1	6	47
Investments ⓘ	92	96	101	100	98	107	117	110	121	121
Inventories	3	3	3	5	6	4	5	2	4	15
Trade Receivables	16	15	21	23	17	23	41	53	62	83
Cash Equivalents	3	2	4	4	3	6	2	18	19	7
Others Assets ⓘ	3	4	9	32	42	49	50	51	58	61
Total Assets ⓘ	125	128	144	171	173	195	231	250	285	355

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	18	1	-1	7	7	6	5	6	-3	15
PBT ⓘ	-2	-0	7	20	5	8	14	19	23	41
Adjustment ⓘ	1	1	-1	-3	-4	-0	0	2	2	-6
Changes in Working Capital ⓘ	20	0	-7	-5	9	0	-6	-11	-21	-11
Tax Paid ⓘ	-0	0	-0	-4	-2	-1	-3	-4	-7	-8
Cash Flow From Investing Activity ⓘ +	-20	-1	-2	-22	-10	-5	-16	6	-9	-41
Capex	0	-1	-1	-2	-1	-0	-8	-4	-7	-47
Net Investments	-20	0	-2	2	0	-0	-7	7	-2	5
Others ⓘ	-1	-0	1	-22	-9	-5	-1	3	-1	1
Cash Flow From Financing Activity ⓘ +	-0	-0	6	15	1	2	8	3	11	16
Net Proceeds from Shares ⓘ	0	0	3	0	0	0	0	0	4	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	28
Interest Paid ⓘ	0	0	0	0	0	0	-1	-1	-2	-2
Dividend Paid ⓘ	-0	-0	-0	-1	-2	0	0	0	0	0
Others ⓘ	0	0	3	15	3	2	8	4	9	-10
Net Cash Flow ⓘ	-2	-0	2	0	-1	3	-3	15	0	-11

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-1.75	-0.03	5.06	10.65	2.97	3.93	6.23	8.59	8.51	13.11
ROCE (%)	-2.04	-0.26	6.01	13.79	3.79	4.91	7.83	9.9	10.75	15.49
Asset Turnover Ratio	0.17	0.22	0.37	0.61	0.35	0.38	0.49	0.49	0.49	0.57
PAT to CFO Conversion(x)	N/A	N/A	-0.17	0.47	1.75	1	0.45	0.38	-0.17	0.48
Working Capital Days
Receivable Days	251.70	200.60	127.40	83	120.50	103.80	111.70	146.50	159.40	145.90
Inventory Days	43.40	33.80	19.40	14.20	30.80	23.80	14.90	10.90	8.40	19.40
Payable Days	125.10	150.10	93.60	45.20	68.30	100.30	125.20	176.60	151.60	145.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kilitch Drugs (India) Ltd FAQs

The current trading price of Kilitch Drugs(India) on 04-Jun-2026 16:59 is ₹179.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Kilitch Drugs(India) stood at ₹625.8 Cr

The latest P/E ratio of Kilitch Drugs(India) as of 03-Jun-2026 is 19.32.

The latest P/B ratio of Kilitch Drugs(India) as of 03-Jun-2026 is 1.88.

The 52-week high of Kilitch Drugs(India) is ₹245.0 and the 52-week low is ₹121.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kilitch Drugs(India) is ₹189 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kilitch Drugs (India) Ltd is a below average quality company.

The key valuation ratios of Kilitch Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Kilitch Drugs (India) Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Kilitch Drugs (India) Ltd

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

Kilitch Drugs (India) Ltd (KILITCH)

Kilitch Drugs (India) Ltd (KILITCH)

Kilitch Drugs (India) stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Kilitch Drugs(India) - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kilitch Drugs (India) Ltd FAQs

About Kilitch Drugs (India) Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Kilitch Drugs (India) Ltd (KILITCH)

Kilitch Drugs (India) Ltd (KILITCH)

Kilitch Drugs (India) stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Kilitch Drugs(India) - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Kilitch Drugs (India) Ltd FAQs

What is the share price of Kilitch Drugs(India)?

What is the market cap of Kilitch Drugs(India)?

What is the P/E ratio of Kilitch Drugs(India)?

What is the P/B ratio of Kilitch Drugs(India)?

What is the 52-week high and low of Kilitch Drugs(India)?

What is the TTM revenue of Kilitch Drugs(India)?

Is Kilitch Drugs (India) Ltd a good quality company?

Is Kilitch Drugs (India) Ltd undervalued or overvalued?

Is Kilitch Drugs (India) Ltd a good buy now?

About Kilitch Drugs (India) Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.